ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.750,92
-0,31%
S&P 500
5.308,13
0,09%
US Dollar vs BRL
5,1041
-0,01%
Bitcoin
71.118,66
-0,46%
Brent Oil
82,345
-1,42%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Prothena Corporation PLC (PRTA)

  7. Prothena Corporation PLC (PRTA) Notícias

PRTA

Prothena (PRTA)

Prothena Corporation PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRTA
DataHoraFonteTítuloCódigoCompanhia
17/05/202417:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
17/05/202417:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
08/05/202417:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRTAProthena Corporation PLC
08/05/202417:05Business WireProthena Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/05/202417:05Business WireProthena to Report First Quarter 2024 Financial Results on May 8NASDAQ:PRTAProthena Corporation PLC
15/04/202417:05Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaNASDAQ:PRTAProthena Corporation PLC
05/03/202423:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
05/03/202418:05Business WireProthena to Participate in Upcoming Healthcare ConferencesNASDAQ:PRTAProthena Corporation PLC
04/03/202418:05Business WireProthena Appoints David Ford to Newly Created Chief People Officer PositionNASDAQ:PRTAProthena Corporation PLC
22/02/202419:29Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PRTAProthena Corporation PLC
22/02/202418:56Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRTAProthena Corporation PLC
21/02/202418:05Business WireProthena Announces Appointment of Daniel G. Welch as Director and Chair DesignateNASDAQ:PRTAProthena Corporation PLC
15/02/202418:05Business WireProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
14/02/202414:16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PRTAProthena Corporation PLC
13/02/202421:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRTAProthena Corporation PLC
08/02/202418:05Business WireProthena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024NASDAQ:PRTAProthena Corporation PLC
24/01/202418:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PRTAProthena Corporation PLC
08/01/202410:30Business WireProthena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio ProgramsNASDAQ:PRTAProthena Corporation PLC
02/11/202317:05Business WireProthena Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
26/10/202317:05Business WireProthena to Report Third Quarter 2023 Financial Results on November 2NASDAQ:PRTAProthena Corporation PLC
03/08/202318:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRTAProthena Corporation PLC
03/08/202317:05Business WireProthena Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
27/07/202317:05Business WireProthena to Report Second Quarter 2023 Financial Results on August 3NASDAQ:PRTAProthena Corporation PLC
17/07/202309:35Business WireProthena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)NASDAQ:PRTAProthena Corporation PLC
11/07/202317:05Business WireProthena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)NASDAQ:PRTAProthena Corporation PLC
10/07/202317:10Business WireProthena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau AntibodyNASDAQ:PRTAProthena Corporation PLC
27/06/202317:05Business WireProthena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with BirtamimabNASDAQ:PRTAProthena Corporation PLC
21/06/202307:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRTAProthena Corporation PLC
20/06/202317:39Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:PRTAProthena Corporation PLC
02/06/202317:05Business WireProthena to Participate in Jefferies 2023 Healthcare ConferenceNASDAQ:PRTAProthena Corporation PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRTA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
COGN3
COGNA ON
BOV
CASH3
Meliuz S.A ON
BOV
INBR32
Inter &
BOV
GOLL4
GOL PN
BOV
LUPA3
LUPATECH ON
BOV
LWSA3
LOCAWEB ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados